Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Income Statement
Earnings Waterfall
Arcutis Biotherapeutics Inc
Revenue
|
59.6m
USD
|
Cost of Revenue
|
-5m
USD
|
Gross Profit
|
54.6m
USD
|
Operating Expenses
|
-295.7m
USD
|
Operating Income
|
-241.1m
USD
|
Other Expenses
|
-21m
USD
|
Net Income
|
-262.1m
USD
|
Income Statement
Arcutis Biotherapeutics Inc
Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
4
+405%
|
6
+75%
|
12
+80%
|
49
+321%
|
60
+22%
|
|
Gross Profit | ||||||||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(2)
|
(2)
|
(3)
|
(5)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
3
+537%
|
5
+69%
|
9
+89%
|
46
+390%
|
55
+19%
|
|
Operating Income | ||||||||||||||||||||
Operating Expenses |
(29)
|
(36)
|
(43)
|
(65)
|
(92)
|
(116)
|
(137)
|
(144)
|
(151)
|
(169)
|
(207)
|
(233)
|
(257)
|
(305)
|
(305)
|
(320)
|
(326)
|
(294)
|
(296)
|
|
Selling, General & Administrative |
(3)
|
(5)
|
(7)
|
(9)
|
(14)
|
(17)
|
(21)
|
(32)
|
(38)
|
(49)
|
(61)
|
(69)
|
(85)
|
(104)
|
(122)
|
(143)
|
(161)
|
(174)
|
(185)
|
|
Research & Development |
(26)
|
(31)
|
(37)
|
(56)
|
(78)
|
(99)
|
(115)
|
(112)
|
(113)
|
(120)
|
(146)
|
(165)
|
(172)
|
(201)
|
(182)
|
(177)
|
(164)
|
(121)
|
(111)
|
|
Operating Income |
(29)
N/A
|
(36)
-24%
|
(43)
-20%
|
(65)
-50%
|
(92)
-42%
|
(116)
-26%
|
(137)
-18%
|
(144)
-5%
|
(151)
-4%
|
(169)
-12%
|
(207)
-22%
|
(233)
-13%
|
(257)
-10%
|
(305)
-19%
|
(302)
+1%
|
(315)
-5%
|
(316)
0%
|
(248)
+21%
|
(241)
+3%
|
|
Pre-Tax Income | ||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(4)
|
(9)
|
(16)
|
(21)
|
(26)
|
(29)
|
(30)
|
|
Total Other Income |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
6
|
9
|
12
|
12
|
12
|
|
Pre-Tax Income |
(28)
N/A
|
(35)
-24%
|
(42)
-20%
|
(63)
-51%
|
(90)
-43%
|
(114)
-26%
|
(136)
-19%
|
(144)
-6%
|
(150)
-5%
|
(169)
-12%
|
(206)
-22%
|
(235)
-14%
|
(260)
-11%
|
(311)
-20%
|
(311)
0%
|
(327)
-5%
|
(331)
-1%
|
(265)
+20%
|
(259)
+2%
|
|
Net Income | ||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(3)
|
|
Income from Continuing Operations |
(28)
|
(35)
|
(42)
|
(63)
|
(90)
|
(114)
|
(136)
|
(144)
|
(150)
|
(169)
|
(206)
|
(235)
|
(260)
|
(311)
|
(311)
|
(327)
|
(331)
|
(268)
|
(262)
|
|
Net Income (Common) |
(28)
N/A
|
(35)
-24%
|
(42)
-20%
|
(63)
-51%
|
(90)
-43%
|
(114)
-26%
|
(136)
-19%
|
(144)
-6%
|
(150)
-5%
|
(169)
-12%
|
(206)
-22%
|
(235)
-14%
|
(260)
-11%
|
(311)
-20%
|
(311)
0%
|
(327)
-5%
|
(331)
-1%
|
(268)
+19%
|
(262)
+2%
|
|
EPS (Diluted) |
-0.77
N/A
|
-0.96
-25%
|
-1.15
-20%
|
-2.61
-127%
|
-2.4
+8%
|
-3.02
-26%
|
-3.8
-26%
|
-3.03
+20%
|
-3
+1%
|
-3.37
-12%
|
-4.18
-24%
|
-4.64
-11%
|
-5.05
-9%
|
-5.44
-8%
|
-5.66
-4%
|
-5.34
+6%
|
-5.38
-1%
|
-4.33
+20%
|
-3.78
+13%
|